RIGVIR
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
RIGVIR is a virotherapy medication that utilizes a live, non-pathogenic virus to target and destroy cancer cells. It is primarily used in the treatment of melanoma, a type of skin cancer. RIGVIR is notable for being one of the first oncolytic virotherapies to be approved for clinical use.
History[edit | edit source]
RIGVIR was developed in the 1960s and 1970s by a team of researchers led by Professor Aina Muceniece in Latvia. The name "RIGVIR" is derived from "Riga virus," as it was developed in the city of Riga. It was officially registered in Latvia in 2004 for the treatment of melanoma.
Mechanism of Action[edit | edit source]
RIGVIR is based on the ECHO-7 virus, a member of the Enterovirus genus. The virus selectively infects and replicates within cancer cells, leading to their destruction. This process is known as oncolysis. RIGVIR also stimulates the immune system to recognize and attack cancer cells, enhancing its therapeutic effect.
Clinical Use[edit | edit source]
RIGVIR is administered via intramuscular injection. It is used as an adjuvant therapy in the treatment of melanoma, particularly in early stages of the disease. The treatment protocol involves multiple injections over a period of time, tailored to the patient's response and disease progression.
Efficacy and Safety[edit | edit source]
Clinical studies have shown that RIGVIR can improve survival rates and reduce the risk of metastasis in melanoma patients. However, its efficacy and safety profile have been subjects of debate, with some experts calling for more rigorous clinical trials to validate its benefits.
Regulatory Status[edit | edit source]
RIGVIR is approved for use in Latvia and some other countries, but it is not widely accepted or available in many parts of the world, including the United States and Western Europe. The lack of large-scale, randomized controlled trials has limited its acceptance in the global medical community.
Controversies[edit | edit source]
The use of RIGVIR has been controversial due to the limited availability of robust clinical data supporting its efficacy. Critics argue that more comprehensive studies are needed to establish its role in cancer treatment. Additionally, there have been concerns about the marketing and regulation of RIGVIR in some regions.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
